Nurphoto | Nurphoto | Getty ImagesPfizer is ready to move on from Covid. Now, the company is betting on cancer drugs to help it regain its footing after a rocky year marked by the rapid decline of its Covid business. It just might take a while before that bet pays off. Pfizer pitched its deeper push into oncology during a four-hour investor event last week. And it had a splashy 60-second Super Bowl ad that touted its initiative to "outdo cancer." The shift comes at a crucial time for Pfizer. The pharmaceuti ...

JHVEPhotoPfizer's (NYSE:PFE) stock has cratered following the end of its freefall profits from COVID-related vaccine sales. In fact, Pfizer's stock is down by nearly 55% from its ATH in late 2021 and roughly 50% below its high in late 2022. Pfizer's market cap melted from over $330 billion to around $150 billion, approximately a 13-year low. Market cap (companiesmarketcap.com )However, despite Pfizer's post-COVID-19 melt-up and subsequent meltdown, it remains a solid market-leading company with consider ...

Per Cantor Fitzgerald analyst Louise Chen's calculations published March 4, Pfizer's (PFE 4.26%) stock is going to climb by around 75% to reach or surpass $45 over the coming quarters. Chen's hypothesis for the biopharma is likely linked to its ongoing pivot away from its coronavirus medicines like Paxlovid and Comirnaty, and toward the revenue sources of the future, which management has designated as cancer therapeutics.But is Pfizer a buy today, with a price tag around $26, and with its new oncology pipel ...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced data from a planned interim analysis of the LATITUDE phase III trial, indicating that their long-acting injectable antiretroviral treatment (ART) for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of ART adherence c ...

LONDON--(BUSINESS WIRE)--Today, ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, and the American Academy of HIV Medicine (AAHIVM) jointly announced the launch of The Dr. Dawn K. Smith HIV Prevention Clinical Fellowship. The fellowship will provide comprehensive HIV training to non-infectious disease clinicians serving communities disproportionately affected by HIV. The fellowship was announced at the Conference on Retroviruses and Opportuni ...

Pfizer Inc. (NYSE:PFE) TD Cowen 44th Annual Health Care Conference March 4, 2024 11:10 AM ET Company Participants David Denton - Chief Financial Officer and Executive Vice President Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again. We're delighted to have Pfizer here at Cowen's 44th Annual Healthcare Conference. Representing the company, Dave Denton, who is Chief Financial Officer as well as Executive Vice President, will start out. Dave is going to give a few th ...

Pfizer Inc. (NYSE:PFE) TD Cowen 44th Annual Health Care Conference March 4, 2024 11:10 AM ET Company Participants David Denton - Chief Financial Officer and Executive Vice President Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again. We're delighted to have Pfizer here at Cowen's 44th Annual Healthcare Conference. Representing the company, Dave Denton, who is Chief Financial Officer as well as Executive Vice President, will start out. Dave is going to give a few th ...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from its phase I study showing that an investigational formulation of cabotegravir, known as cabotegravir ultra long-acting (CAB-ULA), can be dosed at intervals of at least four months. This is the company’s first step towards delivering ultra long-acting injectable HIV treatment and prevention medicines that would potentially enable p ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this drugmaker have returned -1.3% over the past month versus the Zacks S&P 500 composite's +4.8% change. The Zacks Large Cap Pharmaceuticals industry, to which Pfizer belongs, has gained 6% over this period. Now the key question is: Where could the stock be headed in the near term?Although media reports or r ...

olm26250 Introduction Over the past few weeks, I have often told people I'm getting a 2021 feeling, as the market is rapidly rising, boosted by a few select tech/growth stocks. Meanwhile, crypto assets are flying again, boosted by Federal Reserve rate expectations that may not be fully justified in light of sticky inflation. The other day, Bloomberg wrote an article titled The Casino Crowd Is Back Across Markets With Soft Echoes Of 2021." According to the article, retail investors, who largely remained ...